NASDAQ:KALA Kala Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kala Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.36 -0.58 (-6.49 %) (As of 09/22/2020 12:00 AM ET) Add Compare Share Today's Range$8.35Now: $8.36▼$9.2350-Day Range$7.96MA: $8.84▼$9.8352-Week Range$3.24Now: $8.36▼$14.68Volume1.07 million shsAverage Volume1.13 million shsMarket Capitalization$468.66 millionP/E RatioN/ADividend YieldN/ABeta0.24 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingKala Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.71, Kala Pharmaceuticals has a forecasted upside of 135.8% from its current price of $8.36.Amount of Analyst CoverageKala Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesKala Pharmaceuticals has received 273 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKala Pharmaceuticals has received 255 “underperform” votes. (Add your “underperform” vote.)Community SentimentKala Pharmaceuticals has received 51.70% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. Vote “Outperform” if you believe KALA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KALA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKala Pharmaceuticals does not currently pay a dividend.Dividend GrowthKala Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kala Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 34.15% of the stock of Kala Pharmaceuticals is held by insiders.Percentage Held by Institutions76.50% of the stock of Kala Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kala Pharmaceuticals are expected to grow in the coming year, from ($1.72) to ($1.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kala Pharmaceuticals is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kala Pharmaceuticals is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKala Pharmaceuticals has a P/B Ratio of 9.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.53 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KALA Previous Symbol CUSIPN/A CIK1479419 Webwww.kalarx.com Phone781-996-5252Debt Debt-to-Equity Ratio0.56 Current Ratio11.63 Quick Ratio11.29Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.07 million Price / Sales77.21 Cash FlowN/A Price / Cash FlowN/A Book Value$0.86 per share Price / Book9.72Profitability EPS (Most Recent Fiscal Year)($2.76) Net Income$-94,350,000.00 Net Margins-1,993.41% Return on Equity-105.36% Return on Assets-44.13%Miscellaneous Employees136 Outstanding Shares56,060,000Market Cap$468.66 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $8.36 -0.58 (-6.49 %) (As of 09/22/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive KALA News and Ratings via Email Sign-up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter. Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions How has Kala Pharmaceuticals' stock been impacted by COVID-19? Kala Pharmaceuticals' stock was trading at $7.63 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KALA shares have increased by 9.6% and is now trading at $8.36. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Kala Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kala Pharmaceuticals. When is Kala Pharmaceuticals' next earnings date? Kala Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Kala Pharmaceuticals. How were Kala Pharmaceuticals' earnings last quarter? Kala Pharmaceuticals Inc (NASDAQ:KALA) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.42) EPS for the quarter, hitting analysts' consensus estimates of ($0.42). The company earned $0.83 million during the quarter, compared to the consensus estimate of $0.76 million. Kala Pharmaceuticals had a negative net margin of 1,993.41% and a negative return on equity of 105.36%. View Kala Pharmaceuticals' earnings history. What price target have analysts set for KALA? 7 brokerages have issued 1 year target prices for Kala Pharmaceuticals' shares. Their forecasts range from $10.00 to $39.00. On average, they anticipate Kala Pharmaceuticals' stock price to reach $19.71 in the next year. This suggests a possible upside of 135.8% from the stock's current price. View analysts' price targets for Kala Pharmaceuticals. Are investors shorting Kala Pharmaceuticals? Kala Pharmaceuticals saw a increase in short interest in August. As of August 31st, there was short interest totaling 5,800,000 shares, an increase of 35.2% from the August 15th total of 4,290,000 shares. Based on an average daily trading volume, of 897,600 shares, the short-interest ratio is currently 6.5 days. View Kala Pharmaceuticals' Short Interest. Who are some of Kala Pharmaceuticals' key competitors? Some companies that are related to Kala Pharmaceuticals include Aurinia Pharmaceuticals (AUPH), Akcea Therapeutics (AKCA), Revance Therapeutics (RVNC), Uniqure (QURE), CryoPort (CYRX), Prestige Consumer Healthcare (PBH), Eidos Therapeutics (EIDX), Kura Oncology (KURA), Ironwood Pharmaceuticals (IRWD), Y-mAbs Therapeutics (YMAB), Amarin (AMRN), Dicerna Pharmaceuticals (DRNA), Cytokinetics (CYTK), Ligand Pharmaceuticals (LGND) and ZEALAND PHARMA/S (ZEAL). View all competitors. What other stocks do shareholders of Kala Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Pfizer (PFE), Bristol-Myers Squibb (BMY), Dynavax Technologies (DVAX), Micron Technology (MU), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), AbbVie (ABBV), Amarin (AMRN) and Alibaba Group (BABA). Who are Kala Pharmaceuticals' key executives? Kala Pharmaceuticals' management team includes the following people: Mr. Mark T. Iwicki, Chairman, Pres & CEO (Age 54, Pay $871.14k)Mr. Todd Bazemore, Chief Operating Officer (Age 50, Pay $607.5k)Mr. Eric L. Trachtenberg, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 47, Pay $646.56k)Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory BoardMs. Mary Reumuth CPA, CPA, CFO & Treasurer (Age 45) When did Kala Pharmaceuticals IPO? (KALA) raised $90 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers. What is Kala Pharmaceuticals' stock symbol? Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA." Who are Kala Pharmaceuticals' major shareholders? Kala Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (8.35%), Vanguard Group Inc. (3.93%), Sofinnova Investments Inc. (0.90%), Bank of America Corp DE (0.71%), Opaleye Management Inc. (0.64%) and Assenagon Asset Management S.A. (0.65%). Company insiders that own Kala Pharmaceuticals stock include Gregory Grunberg, Howard B Rosen, Ra Capital Healthcare Fund Lp, Rajeev M Shah and Todd Bazemore. View institutional ownership trends for Kala Pharmaceuticals. Which institutional investors are selling Kala Pharmaceuticals stock? KALA stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Alyeska Investment Group L.P., Goldman Sachs Group Inc., Matisse Capital, Tudor Investment Corp Et Al, Lindbrook Capital LLC, Wedbush Securities Inc., and UBS Group AG. View insider buying and selling activity for Kala Pharmaceuticals. Which institutional investors are buying Kala Pharmaceuticals stock? KALA stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Assenagon Asset Management S.A., Vanguard Group Inc., Federated Hermes Inc., Barclays PLC, Sofinnova Investments Inc., Ensign Peak Advisors Inc, and Nuveen Asset Management LLC. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Gregory Grunberg, Howard B Rosen, Ra Capital Healthcare Fund Lp, Rajeev M Shah, and Todd Bazemore. View insider buying and selling activity for Kala Pharmaceuticals. How do I buy shares of Kala Pharmaceuticals? Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Kala Pharmaceuticals' stock price today? One share of KALA stock can currently be purchased for approximately $8.36. How big of a company is Kala Pharmaceuticals? Kala Pharmaceuticals has a market capitalization of $468.66 million and generates $6.07 million in revenue each year. The company earns $-94,350,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis. Kala Pharmaceuticals employs 136 workers across the globe. What is Kala Pharmaceuticals' official website? The official website for Kala Pharmaceuticals is www.kalarx.com. How can I contact Kala Pharmaceuticals? Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. The company can be reached via phone at 781-996-5252 or via email at [email protected] This page was last updated on 9/22/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
